European Society
For Medical Oncology

Findings from the TUXEDO-1 study

Findings from the ARCAGEN study (EORTC-1843)

Findings from an analysis of data from two ovarian cancer consortia

Genetic testing, along with assessment of clinical risk factors, could be used to identify survivors at high risk for severe obesity and associated cardio-metabolic complications

This radiopharmaceutical precursor must be used only for the radiolabelling of carrier medicines that have been specifically developed and authorised for radiolabelling with lutetium chloride

Findings from a comprehensive analysis of the clinicopathologic, genomic, and immunophenotypic correlates of KRAS^G12D-mutated non-small cell lung cancer

Findings from the LEAP-004 study

Findings from the STO-5 study

Findings from the TOTEM study 

The ESMO World Congress on Gastrointestinal Cancer, the annual event dedicated to the presentation and discussion of new findings in GI cancer treatment, research and care, will be held as a fully onsite event in Barcelona, Spain, from 29 June to 2 July 2022.

Data from two large cancer centres in the United States have shown that the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care.

The ESMO Gynaecological Cancers Congress 2022, the annual event dedicated to improving the practice of gynaecological cancers specialists worldwide, will provide insights into the latest treatments, biology and biomarkers of ovarian, uterine, cervical and rare cancers.

The evidence-based tool is designed to help interpret data from a heterogeneous research landscape

The ESMO Breast Cancer Congress 2022, the annual event dedicated to advancing the science, disseminating education and improving the practice of breast cancer specialists worldwide, will focus this year on integrating translational research for innovative clinical practice.

A consensus reached by a lung clinical community within the International Cancer Benchmarking Partnership (ICBP), presented at the ELCC, 30 March – 2 April 2022, has highlighted international disparities in management and outcomes of patients with lung cancer in high-income countries, and has provided a roadmap of key actions that should be taken to homogenise practices, help enable earlier diagnosis and offer equitable access to care.  

More than half of patients diagnosed with advanced non-small cell lung cancer (NSCLC) undergo biomarker testing, and this figure has increased over the last five years, reveal real-world data from a Spanish national registry study reported at the European Lung Cancer Congress (ELCC), 30 March-2 April 2022.

The European Lung Cancer Congress 2022 (ELCC), the annual event dedicated to advancing the science, disseminating education and improving the practice of lung cancer specialists worldwide, will be held as a virtual meeting. 

Original data presentations by the authors of the OlympiA and PEARLS/KEYNOTE-091 trials will be followed by critical analysis and discussion with a panel of renowned experts.

ESMO has announced today the winners of the 2022 ESMO Society Awards.

ESMO has announced today the results of its Executive Board elections following the closure of the voting system on Monday 27 June 2022.

ESMO has announced today that the 2022 ESMO Breast Cancer Award is presented to Sibylle Loibl for her exceptional contribution to clinical research in breast cancer.  

In light of the challenging situation in Prague due to the ongoing arrival of refugees from Ukraine

ESMO expresses profound sadness about the unfolding tragedy in Ukraine and the suffering of people

Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose 

ESMO President will act as an Advisor

The 2022 ESMO Heine H. Hansen Award is conferred on Fred R. Hirsch for his lifelong outstanding contribution to lung cancer research

Who will be the next ESMO Awardees? Submit your nominations before 9 March.